Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

PubWeight™: 1.29‹?› | Rank: Top 10%

🔗 View Article (PMC 114147)

Published in J Virol on May 01, 2001

Authors

K Mori1, Y Yasutomi, S Ohgimoto, T Nakasone, S Takamura, T Shioda, Y Nagai

Author Affiliations

1: AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Articles citing this

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med (2004) 2.99

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol (2002) 2.63

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol (2008) 1.72

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67

Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol (2013) 1.15

nef gene is required for robust productive infection by simian immunodeficiency virus of T-cell-rich paracortex in lymph nodes. J Virol (2003) 1.07

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol (2005) 1.07

Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J Immunol (2009) 1.02

Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology (2009) 1.01

Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol (2005) 0.99

Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol (2005) 0.99

Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model. J Virol (2005) 0.98

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol (2005) 0.98

N-linked glycosylation status of classical swine fever virus strain Brescia E2 glycoprotein influences virulence in swine. J Virol (2006) 0.93

Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. PLoS One (2010) 0.90

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine. J Virol (2003) 0.88

Functional contributions of carbohydrate on AIDS virus glycoprotein. Yale J Biol Med (2010) 0.87

Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions. Retrovirology (2013) 0.83

Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A (2015) 0.82

Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus. J Virol (2012) 0.81

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80

Early bone marrow hematopoietic defect in simian/human immunodeficiency virus C2/1-infected macaques and relevance to advance of disease. J Virol (2004) 0.79

Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol (2010) 0.79

Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection. Virology (2008) 0.78

Glycosylation of simian immunodeficiency virus influences immune-tissue targeting during primary infection, leading to immunodeficiency or viral control. J Virol (2012) 0.77

Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine. PLoS Pathog (2016) 0.75

Simian Immunodeficiency Virus Targeting of CXCR3(+) CD4(+) T Cells in Secondary Lymphoid Organs Is Associated with Robust CXCL10 Expression in Monocyte/Macrophage Subsets. J Virol (2017) 0.75

Articles cited by this

Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem (1990) 8.98

Cytotoxic T-cell memory without antigen. Nature (1994) 6.55

The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79

Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature (1994) 5.49

A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06

The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (1999) 3.57

Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol (1993) 3.27

Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med (1999) 3.11

Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90

Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol (1997) 2.88

Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol (1997) 2.59

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol (1999) 2.48

Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol (1998) 1.98

Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol (1998) 1.90

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71

T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr Opin Immunol (1999) 1.68

Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.61

Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol (1998) 1.39

Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc Natl Acad Sci U S A (1999) 1.35

Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med (1999) 1.31

Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol (2000) 1.28

Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol Rev (1999) 1.23

Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. J Virol (1998) 1.09

Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface. J Virol (1996) 1.08

Induction of MHC-IIDR expression on circulating CD8+ lymphocytes in macaques infected with SIVmac239 nef-open but not with its nef-deletion mutant. AIDS Res Hum Retroviruses (1998) 0.95

Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol (1998) 0.92

Humoral immunity to HIV, SIV, and SHIV. AIDS (1998) 0.91

Articles by these authors

Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet (2001) 18.55

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23

Complete genome sequence of an aerobic hyper-thermophilic crenarchaeon, Aeropyrum pernix K1. DNA Res (1999) 7.39

Complete sequence and gene organization of the genome of a hyper-thermophilic archaebacterium, Pyrococcus horikoshii OT3. DNA Res (1998) 6.79

Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology (1976) 4.85

Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med (2000) 3.74

Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71

Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins. Nucleic Acids Res (1983) 3.62

Tadpole collagenase. Preparation and purification. Biochemistry (1966) 3.50

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells (1996) 3.41

In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34

A glycolipid on the surface of mouse natural killer cells. Eur J Immunol (1980) 3.13

Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10

p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J (1993) 3.06

Complete genome sequence of an aerobic thermoacidophilic crenarchaeon, Sulfolobus tokodaii strain7. DNA Res (2001) 2.99

Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol (1991) 2.87

The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J (1997) 2.71

Specific degradation of the collagen molecule by tadpole collagenolytic enzyme. Proc Natl Acad Sci U S A (1965) 2.61

Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res (1986) 2.60

Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology (1983) 2.53

Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology (1987) 2.46

A woman who trembled, then had chorea. Lancet (1998) 2.40

RNA packaging signal of human immunodeficiency virus type 1. Virology (1992) 2.38

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20

Recovery of pathogenic measles virus from cloned cDNA. J Virol (2000) 2.19

Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17

PAR-6 regulates aPKC activity in a novel way and mediates cell-cell contact-induced formation of the epithelial junctional complex. Genes Cells (2001) 2.13

Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage. Virology (1977) 2.00

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol (2000) 1.92

Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. FEBS Lett (1999) 1.92

Mammalian subtilisin-related proteinases in cleavage activation of the paramyxovirus fusion glycoprotein: superiority of furin/PACE to PC2 or PC1/PC3. J Virol (1992) 1.91

Complete sequence and gene organization of the genome of a hyper-thermophilic archaebacterium, Pyrococcus horikoshii OT3 (supplement). DNA Res (1998) 1.81

Ototoxicity of neomycin and its penetration through the round window membrane into the perilymph. Ann Otol Rhinol Laryngol (1986) 1.80

X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation. Dev Biol (2000) 1.80

A rapid and micro method for separation of acidic glycosaminoglycans by two-dimensional electrophoresis. Anal Biochem (1972) 1.76

Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71

Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71

The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med (2000) 1.71

The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem (2000) 1.70

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A (1997) 1.68

An endoprotease homologous to the blood clotting factor X as a determinant of viral tropism in chick embryo. EMBO J (1990) 1.66

Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol (1999) 1.66

Newcastle disease virus evolution. II. Lack of gene recombination in generating virulent and avirulent strains. Virology (1989) 1.64

New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med (1999) 1.62

Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells (1998) 1.62

Isolation and properties of human blood-group NN and meconium-Vg antigens. Biochemistry (1966) 1.61

Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology (1993) 1.60

Mechanical compression of the extracranial vertebral artery during neck rotation. Neurology (2003) 1.59

Studies on the structure of collagen utilizing a collagenolytic enzyme from tadpole. Biochemistry (1966) 1.59

Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J Virol (1997) 1.58

Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene. Virology (1989) 1.55

Studies on the assembly of the envelope of Newcastle disease virus. Virology (1976) 1.54

Expression of factor X and its significance for the determination of paramyxovirus tropism in the chick embryo. EMBO J (1992) 1.54

Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes Dev (2001) 1.53

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer (2006) 1.53

Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis (1994) 1.52

Dymple, a novel dynamin-like high molecular weight GTPase lacking a proline-rich carboxyl-terminal domain in mammalian cells. J Biol Chem (1998) 1.51

Measles virus attenuation associated with transcriptional impediment and a few amino acid changes in the polymerase and accessory proteins. J Virol (1998) 1.50

Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol (2001) 1.49

Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther (2000) 1.49

A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. Am J Obstet Gynecol (1989) 1.49

Identification of amino acids relevant to three antigenic determinants on the fusion protein of Newcastle disease virus that are involved in fusion inhibition and neutralization. J Virol (1988) 1.49

Hereditary nodular heterotopia accompanied by mega cisterna magna. Am J Med Genet (1993) 1.48

In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol (1997) 1.48

Drug resistance of enteric bacteria. IX. Distribution of R factors in gram-negative bacteria from clinical sources. J Bacteriol (1967) 1.47

Studies on the role of M protein in virus assembly using a ts mutant of HVJ (Sendai virus). Virology (1979) 1.42

The first case of insulin-dependent diabetes mellitus with prominent spurious hyperglucagonemia due to interference of immunoglobulin G in glucagon radioimmunoassay (OAL-123) system. Horm Res (1996) 1.39

Y2, the smallest of the Sendai virus C proteins, is fully capable of both counteracting the antiviral action of interferons and inhibiting viral RNA synthesis. J Virol (2001) 1.39

Effects of antihypertensive agents on circadian blood pressure in hypertensive patients with previous brain infarction. J Hum Hypertens (1997) 1.39

A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1. J Virol (1994) 1.38

Purification of phosphatidylinositol-specific phospholipase C from rat liver. J Biol Chem (1981) 1.37

Identification of glycolipid receptors for Helicobacter pylori by TLC-immunostaining. FEBS Lett (1991) 1.37

Transcriptive complex of Newcastle disease virus. II. Structural and functional assembly associated with the cytoskeletal framework. Virology (1985) 1.36

Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3' proximal first locus. J Gen Virol (1997) 1.35

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol (2001) 1.34

Nucleotide sequence of the bovine parainfluenza 3 virus genome: its 3' end and the genes of NP, P, C and M proteins. Nucleic Acids Res (1987) 1.34

Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus (2011) 1.33

Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role. J Virol (2000) 1.33

Role of Ca2+ in phosphatidylinositol response and arachidonic acid release in formylated tripeptide- or Ca2+ ionophore A23187-stimulated guinea pig neutrophils. J Immunol (1983) 1.33

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer (2007) 1.31

Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30

The relationship between pregnancy outcome and smooth endoplasmic reticulum clusters in MII human oocytes. Hum Reprod (2004) 1.29

Persistent activation of phosphatidylinositol 3-kinase causes insulin resistance due to accelerated insulin-induced insulin receptor substrate-1 degradation in 3T3-L1 adipocytes. Endocrinology (2000) 1.29

Sendai virus C protein physically associates with Stat1. Genes Cells (2001) 1.29

Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol (2000) 1.28

Influenza viruses, cell enzymes, and pathogenicity. Am J Respir Crit Care Med (1995) 1.28

Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27

Inhibitory effect of prostaglandin E2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils. J Biol Chem (1986) 1.26

New type of R factors incapable of inactivating chloramphenicol. J Bacteriol (1972) 1.25

Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension (1990) 1.25

The spread of a pathogenic and an apathogenic strain of Newcastle disease virus in the chick embryo as depending on the protease sensitivity of the virus glycoproteins. J Gen Virol (1979) 1.24

Distribution of R factors among Shigella strains isolated in Japan. Jpn J Microbiol (1969) 1.24